Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

Published on Jun 9, 2021in Frontiers of Medicine in China
· DOI :10.3389/FMED.2021.639970
Augusto Di Castelnuovo39
Estimated H-index: 39
,
Simona Costanzo42
Estimated H-index: 42
+ 107 AuthorsGiovanni Guaraldi58
Estimated H-index: 58
(University of Modena and Reggio Emilia)
Source
Abstract
References40
Newest
Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with COVID-19 to assess the efficacy of LPV/r for the treatment of Cornonavirus disease 19 (COVID-19). Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studie...
Source
#1Salman Ali Khan (KU: University of Karachi)H-Index: 3
#2Komal Zia (KU: University of Karachi)H-Index: 3
Last. Zaheer Ul-Haq (KU: University of Karachi)H-Index: 19
view all 5 authors...
Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard dru...
Source
#1Jovana Milic (University of Modena and Reggio Emilia)H-Index: 11
#2Alessio Novella (Mario Negri Institute for Pharmacological Research)H-Index: 3
Last. Giovanni Guaraldi (University of Modena and Reggio Emilia)H-Index: 58
view all 25 authors...
Background The aim of this study was to evaluate both positive outcomes, including reduction of respiratory support aid and duration of hospital stay, and negative ones, including mortality and a composite of invasive mechanical ventilation or death, in patients with COVID-19 pneumonia treated with or without oral darunavir/cobicistat (DRV/c, 800/150 mg/day) used in different treatment duration. Secondary objective was to evaluate the percentage of patients treated with DRV/c who were exposed to...
Source
#1Yueping Li (Guangzhou Medical University)H-Index: 10
#2Zhiwei Xie (Guangzhou Medical University)H-Index: 6
Last. Linghua Li (Guangzhou Medical University)H-Index: 17
view all 20 authors...
Background: Antiviral therapies against the novel coronavirus SARS-CoV-2, which has caused a global pandemic of respiratory illness called COVID-19, are still lacking. Methods: Our study (NCT04252885, named ELACOI), was an exploratory randomized (2:2:1) controlled trial assessing the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy for treating patients with mild/moderate COVID-19. Findings: This study successfully enrolled 86 patients with mild/moderate COVID-19 with 34...
Source
#10Marie-Paule Kieny (WHO: World Health Organization)H-Index: 33
Hongchao Pan (University of Oxford. Nuffield Department of Population Health. Medical Research Council Population Health Research Unit. Oxford, United Kingdom); Richard Peto (University of Oxford. Nuffield Department of Population Health. Medical Research Council Population Health Research Unit. Oxford, United Kingdom); Ana-Maria Henao-Restrepo (World Health Organization. Geneva, Switzerland); Marie-Pierre Preziosi (World Health Organization. Geneva, Switzerland); Vasee Sathiyamoorthy (World Hea...
Source
#2Simona CostanzoH-Index: 42
Last. Licia Iacoviello (University of Insubria)H-Index: 81
view all 109 authors...
Abstract Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID−19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418 ) to retrospectively investigate the relationship between RAAS inhibitors and COVID−19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods We analyzed 4069 unselected patients with laboratory-...
Source
#2Simona CostanzoH-Index: 42
Last. Licia Iacoviello (University of Insubria)H-Index: 81
view all 106 authors...
Abstract Background Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. Objective We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality. Methods In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to eve...
Source
Abstract Background and aims There is poor knowledge on characteristics, comorbidities and laboratory measures associated with risk for adverse outcomes and in-hospital mortality in European Countries. We aimed at identifying baseline characteristics predisposing COVID-19 patients to in-hospital death. Methods and results Retrospective observational study on 3,894 patients with SARS-CoV-2 infection hospitalized from February 19th to May 23rd, 2020 and recruited in 30 clinical centres distributed...
Source
#1Peter HorbyH-Index: 72
#2Marion MafhamH-Index: 12
Last. Martin J LandrayH-Index: 57
view all 26 authors...
Summary Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19. Th...
Source
#1Sandra De Meyer (Janssen Pharmaceutica)H-Index: 21
#2Denisa Bojkova (Goethe University Frankfurt)H-Index: 14
Last. Sandra Ciesek (Goethe University Frankfurt)H-Index: 39
view all 8 authors...
Abstract Objectives Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Methods Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with ...
Source
Cited By2
Newest
#1Marco Vinceti (University of Modena and Reggio Emilia)H-Index: 57
#2Tommaso Filippini (University of Modena and Reggio Emilia)H-Index: 28
Last. Nicola Orsini (KI: Karolinska Institutet)H-Index: 65
view all 5 authors...
BACKGROUND: The relation between the magnitude of successive waves of the COVID-19 outbreak within the same communities could be useful in predicting the scope of new outbreaks. METHODS: We investigated the extent to which COVID-19 mortality in Italy during the second wave was related to first wave mortality within the same provinces. We compared data on province-specific COVID-19 2020 mortality in two time periods, corresponding to the first wave (February 24-June 30, 2020) and to the second wa...
Source
Source
#7Steven C. Johnson (CU: University of Colorado Boulder)H-Index: 21
Background:Understanding the relationship between HIV and SARS-CoV-2 has important public health implications. Objective:To summarize current research on COVID-19 among people with HIV (PWH) as published through 15 July 2021. Methods: We conducted a search of PubMed, Scopus, preprint databases (medRxiv, bioRxiv), and the references of publications found using key terms relevant to COVID-19 (‘COVID-19’ OR ‘SARS-CoV-2’ OR ‘coronavirus’) AND to HIV (‘HIV’ OR ‘Human Immunodeficiency Virus’ OR ‘AIDS’...
Source
#2Laura BüttnerH-Index: 3
Last. Georg BöningH-Index: 10
view all 8 authors...
We evaluated a simple semi-quantitative (SSQ) method for determining pulmonary involvement in computed tomography (CT) scans of COVID-19 patients. The extent of lung involvement in the first available CT was assessed with the SSQ method and subjectively. We identified risk factors for the need of invasive ventilation, intensive care unit (ICU) admission and for time to death after infection. Additionally, the diagnostic performance of both methods was evaluated. With the SSQ method, a 10% increa...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.